Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
Sign Up to like & getrecommendations! Published in 2020 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-020-05706-4
Abstract: Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption… read more here.
Keywords: mascc; checkpoint inhibitors; supportive care; management ... See more keywords